US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
Top Cited Papers
Open Access
- 22 June 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (24), 2448-2456
- https://doi.org/10.1001/jama.2021.7517
Abstract
On February 27, 2021, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the single-dose Janssen/Johnson & Johnson COVID-19 (Ad26.COV2.S) vaccine, a replication-incompetent human adenovirus 26 vector vaccine.1 As of April 12, 2021, approximately 7 million doses of this vaccine had been administered nationwide.2,3This publication has 23 references indexed in Scilit:
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- Cerebral Venous Sinus Thromboses in Patients with SARS-CoV-2 Infection: Three Cases and a Review of the LiteratureJournal of Stroke and Cerebrovascular Diseases, 2020
- Cerebral Venous Thrombosis: A Comprehensive ReviewEuropean Neurology, 2020
- Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced ThrombocytopeniaJournal of Blood Medicine, 2020
- Autoimmune heparin‐induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2017
- Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A ReviewMolecules, 2017
- Heparin-induced thrombocytopenia: research and clinical updatesHematology, 2016
- Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorderBlood, 2014
- Diagnosis and Management of Cerebral Venous ThrombosisStroke, 2011
- Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patientsJournal of Neurology, Neurosurgery & Psychiatry, 2001